Europe surveillance initiative profiling the anti-enterococcal activity of telavancin by specimen source from 2004 to 2005
Abstract number: 1733_324
Sahm D., Draghi D., Benton B., Jones M., Krause K., Thornsberry C.
Objectives: Enterococci are frequently associated with hospital-based infections, including bacteraemia. Telavancin (TLV), a novel, rapidly bactericidal lipoglycopeptide, has recently completed two Phase 3 clinical trials for the treatment of complicated skin and skin structure infections. Ongoing trials are assessing TLV for the treatment of hospital-acquired pneumonia. Because TLV will be used in the hospital setting, profiling its activity against enterococci is important.
Methods: A total of 434 Enterococcus faecalis (EF) and 348 E. faecium (EM) isolates were collected from Europe (35 hospital sites in 14 countries) during 20042005. Isolates were centrally tested by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) methodology (M7-A7) against TLV and comparators. Results were analysed according to blood and non-blood specimen sources (SPECs).
Results: The vancomycin-nonsusceptible (VAN-NS) rate for all EF was 5.5% and the VAN-NS rate for EM was 22.7%. The activity of TLV against the EF and EM isolates is shown in the Table.
Conclusion: TLV demonstrated potent activity against all EF and EM isolates, regardless of SPEC. Based on MIC90 values, TLV was 16-fold more potent against vancomycin-susceptible (VAN-S) isolates compared with VAN-NS isolates among EF and EM. This evaluation of TLV activity will provide a baseline for comparison of in vitro activity as clinical development and use continues.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|